As of 2025-01-25, the Relative Valuation of Novavax Inc (NVAX) is (46.15) USD. This relative valuation is based on P/E multiples. With the latest stock price at 9.22 USD, the upside of Novavax Inc based on Relative Valuation is -600.5%.
The range of the Relative Valuation is (39.91) - (55.13) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 22.4x - 32.4x | 27.4x |
| Forward P/E multiples | 22.1x - 31.0x | 24.5x |
| Fair Price | (39.91) - (55.13) | (46.15) |
| Upside | -532.8% - -697.9% | -600.5% |
| Date | P/E |
| 2025-01-24 | -5.18 |
| 2025-01-23 | -5.37 |
| 2025-01-22 | -4.97 |
| 2025-01-21 | -4.95 |
| 2025-01-17 | -4.72 |
| 2025-01-16 | -4.80 |
| 2025-01-15 | -4.81 |
| 2025-01-14 | -4.78 |
| 2025-01-13 | -4.84 |
| 2025-01-10 | -5.24 |
| 2025-01-08 | -5.40 |
| 2025-01-07 | -6.08 |
| 2025-01-06 | -5.49 |
| 2025-01-03 | -4.98 |
| 2025-01-02 | -4.82 |
| 2024-12-31 | -4.52 |
| 2024-12-30 | -4.46 |
| 2024-12-27 | -4.66 |
| 2024-12-26 | -4.76 |
| 2024-12-24 | -4.79 |
| 2024-12-23 | -4.86 |
| 2024-12-20 | -4.89 |
| 2024-12-19 | -4.88 |
| 2024-12-18 | -4.85 |
| 2024-12-17 | -5.06 |
| 2024-12-16 | -5.19 |
| 2024-12-13 | -5.12 |
| 2024-12-12 | -5.07 |
| 2024-12-11 | -4.96 |
| 2024-12-10 | -4.93 |
| 2024-12-09 | -5.10 |
| 2024-12-06 | -5.03 |
| 2024-12-05 | -4.67 |
| 2024-12-04 | -4.67 |
| 2024-12-03 | -4.73 |
| 2024-12-02 | -4.93 |
| 2024-11-29 | -4.90 |
| 2024-11-27 | -4.85 |
| 2024-11-26 | -4.92 |
| 2024-11-25 | -5.24 |
| 2024-11-22 | -4.76 |
| 2024-11-21 | -4.52 |
| 2024-11-20 | -4.53 |
| 2024-11-19 | -4.50 |
| 2024-11-18 | -4.40 |
| 2024-11-15 | -4.12 |
| 2024-11-14 | -4.06 |
| 2024-11-13 | -4.37 |
| 2024-11-12 | -4.76 |
| 2024-11-11 | -5.07 |